WallStSmart

Ridgetech, Inc. (RDGT)vsScienture Holdings, Inc. (SCNX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Ridgetech, Inc. generates 15992% more annual revenue ($132.16M vs $821,320). SCNX leads profitability with a 0.0% profit margin vs -0.9%. RDGT earns a higher WallStSmart Score of 39/100 (F).

RDGT

Hold

39

out of 100

Grade: F

Growth: 4.7Profit: 4.0Value: 6.7Quality: 8.0
Piotroski: 4/9Altman Z: 2.02

SCNX

Avoid

33

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 6.7Quality: 7.0
Piotroski: 4/9Altman Z: 0.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

RDGTUndervalued (+82.8%)

Margin of Safety

+82.8%

Fair Value

$10.36

Current Price

$0.83

$9.53 discount

UndervaluedFair: $10.36Overvalued
SCNXUndervalued (+61.0%)

Margin of Safety

+61.0%

Fair Value

$1.15

Current Price

$0.35

$0.80 discount

UndervaluedFair: $1.15Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RDGT4 strengths · Avg: 9.5/10
Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Return on EquityProfitability
30.2%10/10

Every $100 of equity generates 30 in profit

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
21.4%8/10

Revenue surging 21.4% year-over-year

SCNX3 strengths · Avg: 9.7/10
Price/BookValuation
0.2x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
449.1%10/10

Revenue surging 449.1% year-over-year

Debt/EquityHealth
0.179/10

Conservative balance sheet, low leverage

Areas to Watch

RDGT4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$3.39M3/10

Smaller company, higher risk/reward

Free Cash FlowQuality
$-6.74M2/10

Negative free cash flow — burning cash

Profit MarginProfitability
-0.9%1/10

Currently unprofitable

SCNX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$15.32M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-0.1%2/10

ROE of -0.1% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : RDGT

The strongest argument for RDGT centers on Price/Book, Return on Equity, Debt/Equity. Revenue growth of 21.4% demonstrates continued momentum.

Bull Case : SCNX

The strongest argument for SCNX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 449.1% demonstrates continued momentum.

Bear Case : RDGT

The primary concerns for RDGT are EPS Growth, Market Cap, Free Cash Flow.

Bear Case : SCNX

The primary concerns for SCNX are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

RDGT profiles as a growth stock while SCNX is a hypergrowth play — different risk/reward profiles.

SCNX carries more volatility with a beta of 3.98 — expect wider price swings.

SCNX is growing revenue faster at 449.1% — sustainability is the question.

SCNX generates stronger free cash flow (-3M), providing more financial flexibility.

Bottom Line

RDGT scores higher overall (39/100 vs 33/100) and 21.4% revenue growth. SCNX offers better value entry with a 61.0% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ridgetech, Inc.

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

China Jo-Jo Drugstores, Inc. is a retailer and wholesale distributor of pharmaceutical and other healthcare products in the People's Republic of China. The company is headquartered in Hangzhou, the People's Republic of China.

Visit Website →

Scienture Holdings, Inc.

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

Scienture Holdings, Inc. (SCNX) is a pioneering biotechnology firm focused on transforming the treatment landscape for neurological disorders through its advanced drug development pipeline and a seasoned research team. The company is dedicated to addressing significant unmet medical needs, highlighting its potential to enhance patient outcomes while skillfully navigating regulatory complexities. With a strong emphasis on scientific integrity and strategic collaborations, Scienture is well-positioned to leverage growth opportunities in the burgeoning global healthcare market, particularly as the demand for effective neurological therapies continues to rise.

Want to dig deeper into these stocks?